| Trial ID: | L5339 |
| Source ID: | NCT01508806
|
| Associated Drug: |
Liraglutide
|
| Title: |
Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: Area under the Curve (AUC) | Secondary: AUC (0-t)|Cmax, maximum concentration|tmax, time to reach Cmax|t½, terminal half-life|CLR (renal clearance)|Adverse events
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-08
|
| Completion Date: |
2006-03
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-24
|
| Locations: |
Novo Nordisk Investigational Site, Christchurch, 2856, Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT01508806
|
